PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 17540003-7 2007 We found that acidic sphingomyelinase activity was induced by acidic extracellular pH and that the specific acidic sphingomyelinase inhibitors (perhexiline and desipramine) and siRNA targeting aSMase/smpd1 could inhibit acidic extracellular pH-induced matrix metalloproteinase-9 expression. Desipramine 160-171 sphingomyelin phosphodiesterase 1, acid lysosomal Mus musculus 193-199 19635928-9 2010 Inhalation of the Asm inhibitors amitriptyline, trimipramine, desipramine, chlorprothixene, fluoxetine, amlodipine, or sertraline restored normal ceramide concentrations in murine bronchial epithelial cells, reduced inflammation in the lung of CF mice and prevented infection with Pseudomonas aeruginosa. Desipramine 62-73 sphingomyelin phosphodiesterase 1, acid lysosomal Mus musculus 18-21 17540003-7 2007 We found that acidic sphingomyelinase activity was induced by acidic extracellular pH and that the specific acidic sphingomyelinase inhibitors (perhexiline and desipramine) and siRNA targeting aSMase/smpd1 could inhibit acidic extracellular pH-induced matrix metalloproteinase-9 expression. Desipramine 160-171 sphingomyelin phosphodiesterase 1, acid lysosomal Mus musculus 200-205 30910852-2 2019 Here, we show that elevated aSMase activity and ceramide content were reduced by desipramine treatment in diabetic animals. Desipramine 81-92 sphingomyelin phosphodiesterase 1, acid lysosomal Mus musculus 28-34 33220685-2 2021 It poorly infects mice deficient in acid sphingomyelinase (ASM), a lysosomal enzyme critical for cholesterol efflux, and wild-type mice treated with desipramine that functionally inhibits ASM. Desipramine 149-160 sphingomyelin phosphodiesterase 1, acid lysosomal Mus musculus 188-191 33220685-8 2021 Infection was markedly lower in ASM-deficient and desipramine-treated wild-type mice versus desipramine-treated SCID mice. Desipramine 92-103 sphingomyelin phosphodiesterase 1, acid lysosomal Mus musculus 32-35 30910852-3 2019 The inhibitor of aSMase, desipramine, improved vascular dysfunction in db/db mice. Desipramine 25-36 sphingomyelin phosphodiesterase 1, acid lysosomal Mus musculus 17-23 30910852-4 2019 High glucose (HG)-induced up-regulation of aSMase activity and ceramide levels were restored by treatment with aSMase siRNA or desipramine in endothelial cells. Desipramine 127-138 sphingomyelin phosphodiesterase 1, acid lysosomal Mus musculus 43-49 30910852-5 2019 In addition, aSMase siRNA or desipramine treatment increased the release of nitric oxide (NO) and the phosphorylation of endothelial NO synthase (eNOS) in diabetic mouse aortas and aortic endothelial cells with HG.These results indicate that inhibition of aSMase/ceramide pathway improves endothelium-dependent vascular relaxation (EDR) largely through regulating the eNOS/NO pathway in diabetic animals. Desipramine 29-40 sphingomyelin phosphodiesterase 1, acid lysosomal Mus musculus 256-262 28955042-5 2017 Strikingly, similar to heterozygote expression of SMPD1, either preventative (p-smpd1+/+) or therapeutic (t-smpd1+/+) pharmacological treatment strategies with desipramine - a functional inhibitor of acid sphingomyelinase (FIASMA) - significantly improved liver function and survival. Desipramine 160-171 sphingomyelin phosphodiesterase 1, acid lysosomal Mus musculus 200-221 30550872-3 2019 RAW 264.7 cells were pretreated with desipramine, an ASM inhibitor, prior to LPS challenge in vitro. Desipramine 37-48 sphingomyelin phosphodiesterase 1, acid lysosomal Mus musculus 53-56 30550872-5 2019 Conversely, inhibition of ASM activity by desipramine diminished LPS induced ASM activities and TNF production of RAW 264.7 cells. Desipramine 42-53 sphingomyelin phosphodiesterase 1, acid lysosomal Mus musculus 26-29 30550872-5 2019 Conversely, inhibition of ASM activity by desipramine diminished LPS induced ASM activities and TNF production of RAW 264.7 cells. Desipramine 42-53 sphingomyelin phosphodiesterase 1, acid lysosomal Mus musculus 77-80 30550872-8 2019 Desipramine administration overrode ASM activities in colon, and ameliorated DSS-induced colitis evidenced with the reduced disease activities and the decreased cytokine levels. Desipramine 0-11 sphingomyelin phosphodiesterase 1, acid lysosomal Mus musculus 36-39 30326559-11 2018 Since we were also able to show that the functional inhibitor of SMPD1, desipramine, ameliorates downregulation of CYP mRNA expression and activities in the acute phase of sepsis in wild-type mice, SMPD1 might be an interesting pharmacological target, which should be further investigated. Desipramine 72-83 sphingomyelin phosphodiesterase 1, acid lysosomal Mus musculus 65-70 30326559-11 2018 Since we were also able to show that the functional inhibitor of SMPD1, desipramine, ameliorates downregulation of CYP mRNA expression and activities in the acute phase of sepsis in wild-type mice, SMPD1 might be an interesting pharmacological target, which should be further investigated. Desipramine 72-83 sphingomyelin phosphodiesterase 1, acid lysosomal Mus musculus 198-203 28420138-8 2017 Furthermore, similar results in desipramine-pretreated SMPD1-/- littermates suggest an SMPD1-independent pathway. Desipramine 32-43 sphingomyelin phosphodiesterase 1, acid lysosomal Mus musculus 55-60 28420138-8 2017 Furthermore, similar results in desipramine-pretreated SMPD1-/- littermates suggest an SMPD1-independent pathway. Desipramine 32-43 sphingomyelin phosphodiesterase 1, acid lysosomal Mus musculus 87-92 27571014-12 2016 The ischemia-induced increase in retinal TNF-alpha levels was suppressed by the administration of the ASMase inhibitor desipramine, or by reducing ASMase expression. Desipramine 119-130 sphingomyelin phosphodiesterase 1, acid lysosomal Mus musculus 102-108